Osta Biotechnologies Inc.
TSX VENTURE : OBI

Osta Biotechnologies Inc.

October 21, 2009 08:34 ET

Osta's Cancer Technology Published in a Prestigious Journal

MONTREAL, QUEBEC--(Marketwire - Oct. 21, 2009) - THE ISSUE OF THIS PRESS RELEASE IS LIMITED TO CANADA ONLY. THIS PRESS RELEASE SHOULD NOT BE ISSUED IN THE UNITED STATES THROUGH U.S. NEWS WIRE AGENCIES.

Osta Biotechnologies Inc. (TSX VENTURE:OBI) today announced that the journal Cancer Research, a high impact publication of the American Association of Cancer Research has published a paper in its October 15, 2009 issue containing the data on Osta's novel anti-cancer therapeutic approach and has selected the paper to appear as a highlight. The results summarized in this paper identify Heme Oxygenase-1 (HO-1) as a potential biomarker and therapeutic target for hormone refractory prostate cancer (HRPCA).

The article entitled "A novel experimental Heme Oxygenase-1 targeted therapy for hormone-refractory prostate cancer" is accessible on online and can be found at www.cancerres.aacrjournals.org.

The results contained in this publication demonstrate augmented HO-1 expression in HRPCA tissue relative to hormone-responsive PCA and benign disease. HO-1 gene silencing in HRPCA cells, or exposure of HRPCA cells to Osta's lead small molecule inhibitor of HO-1, significantly reduced cell invasion in vitro and tumor growth & metastasis formation in animal models. These results highlight the clinical potential of targeting HO-1 in cancer.

Dr. Ajay Gupta, Chairman & CEO of Osta commented "The selection of this paper as a highlight in this prestigious journal validates the solid science behind our cancer therapeutic program directed towards the development of novel HO-1 inhibitors to treat advanced cancers."

The company also announced that it is currently focusing on the development of a novel drug for cancer and Alzheimer's disease and has therefore, terminated a license agreement with McGill University that covers the osteoporosis diagnostic test technology. This diagnostic technology constitutes a non-core asset of the company and is not of any interest to the company given its current research focus on therapeutics development.

Osta Biotechnologies Inc.

Osta is a biopharmaceutical company listed on the TSX Venture Exchange (TSX VENTURE:OBI) dedicated to developing novel diagnostics and therapeutics for the aging population particularly in the areas of Cancer, Alzheimer's disease, Osteoporosis, Osteoarthritis and XLH.

Certain information in this press release is forward-looking and is subject to numerous risks and uncertainties. By their nature, such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. These risks include actions of Osta's competitors, and those inherent in scientific research and development.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • Osta Biotechnologies Inc.
    Dr. Ajay Gupta
    Chairman & CEO
    514-626-9519